Regeneron Pharmaceuticals Investor Presentation — May 2024

Document content

Regeneron Corporate Presentation

This non -promotional presentation contains investigational data as well as forward -looking statements; actual results may vary m aterially.2Note regarding forward -looking statements and non -GAAP financial measures

This presentation includes forward -looking statements that involve risks anduncertainties relating tofuture events andthefuture performance ofRegeneron Pharmaceuticals, Inc.("Regeneron" orthe"Company"), andactual events or

results may differ materially from these forward -looking statements .Words such as"anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations ofsuch words, and similar expressions areintended toidentify such

forward -looking statements, although notallforward -looking statements contain these identifying words .These statements concern, and these risks and uncertainties include, among others, thenature, timing, and possible success

andtherapeutic applications ofproducts marketed orotherwise commercialized byRegeneron and/or itscollaborators orlicensees (collectively, "Regeneron's Products") andproduct candidates being developed byRegeneron and/or

itscollaborators orlicensees (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway orplanned, including without limitation EYLEA®HD(aflibercept) Injection 8mg,EYLEA®(aflibercept)

Injection, Dupixent®(dupilumab), Libtayo®(cemiplimab), Praluent®(alirocumab), Kevzara®(sarilumab), Evkeeza®(evinacumab ),Veopoz®(pozelimab ),odronextamab, itepekimab, fianlimab, garetosmab ,linvoseltamab, REGN 5713 -

5714 -5715 ,NTLA -2001 ,Regeneron's other oncology programs (including itscostimulatory bispecific portfolio), Regeneron's and itscollaborators' earlier -stage programs, and theuse ofhuman genetics inRegeneron's research

programs ;thelikelihood and timing ofachieving anyoftheanticipated milestones discussed orreferenced inthis presentation ;safety issues resulting from theadministration ofRegeneron's Products and Regeneron's Product

Candidates inpatients, including serious complications orside effects inconnection with theuseofRegeneron's Products andRegeneron's Product Candidates inclinical trials ;thelikelihood, timing, and scope ofpossible regulatory

approval andcommercial launch ofRegeneron's Product Candidates andnew indications forRegeneron's Products, including those listed above and/or otherwise discussed inthispresentation ;theextent towhich theresults from the

research and development programs conducted byRegeneron and/or itscollaborators may bereplicated inother studies and/or lead toadvancement ofproduct candidates toclinical trials, therapeutic applications, orregulatory

approval ;ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating topatient privacy ;determinations byregulatory and administrative